# US 2015/0105368 A1 · Pyrazolyl quinoxaline kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105368 A1
- Document ID: US20150105368A1
- Status: Published application
- Kind: A1
- Application number: 14/505,020
- Filed: 2014-10-02
- Published: 2015-04-16
- Earliest claimed: 2010-04-30
- Assignees: Astex Therapeutics Limited
- Applicants: Astex Therapeutics Ltd
- Inventors: Gordon SAXTY; Christopher William MURRAY; Valerio BERDINI; Gilbert Ebai BESONG; Christopher Charles Frederick HAMLETT; Christopher Norbert JOHNSON; Steven John WOODHEAD; Michael READER; David Charles REES; Laurence Anne MEVELLEC; Patrick René ANGIBAUD; Eddy Jean Edgard FREYNE; Tom Cornelis Hortense GOVAERTS; Johan Erwin Edmond WEERTS; Timothy Pietro Suren PERERA; Ronaldus Arnodus Hendrika Joseph GILISSEN; Berthold WROBLOWSKI; Jean Fernand Armand LACRAMPE; Alexandra PAPANIKOS; Oliver Alexis Georges QUEROLLE; Elisabeth Thérèse Jeanne PASQUIER; Isabelle Noëlle Constance PILATTE; Pascal Ghislain André BONNET; Werner Constant Johan EMBRECHTS; Rhalid AKKARI; Lieven MEERPOEL
- Web page: https://patentgrep.com/patent/US20150105368A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 487/08: Bridged systems
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07F 9/6524: having four or more nitrogen atoms as the only ring hetero atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

## Claims

### Claim 1

A method for treating a subject suffering from, or being at risk of suffering from a disease state or condition mediated by a FGFR kinase, said method comprising administering to the subject a compound selected from the group consisting of a compound of formula (I)
a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein
n is an integer equal to 0, 1, 2, 3 or 4;
R1 is
hydrogen,
C1-6alkyl,
C2-4alkenyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
cyanoC1-4alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with —NR4R5,
C1-6alkyl substituted with —C(═O)—NR4R5,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R6,
C1-6alkyl substituted with R6,
C1-6alkyl substituted with —C(═O)—R6,
hydroxyC1-6alkyl substituted with R6,
C1-6alkyl substituted with —Si(CH3)3,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
each R1a is independently selected from
hydrogen,
C1-4alkyl,
hydroxyC1-4alkyl,
C1-4alkyl substituted with amino or mono- or di(C1-4alkyl)amino or —NH(C3-8cycloalkyl),
cyanoC1-4alkyl,
C1-4alkoxyC1-4alkyl, and
C1-4alkyl substituted with one or more fluoro atoms;
each R2 is independently selected from
hydroxyl,
halogen,
cyano,
C1-4alkyl,
C2-4alkenyl,
C2-4alkynyl,
C1-4alkoxy,
hydroxyC1-4alkyl,
hydroxyC1-4alkoxy,
haloC1-4alkyl,
haloC1-4alkoxy,
hydroxyhaloC1-4alkyl,
hydroxyhaloC1-4alkoxy,
C1-4alkoxyC1-4alkyl,
haloC1-4alkoxyC1-4alkyl,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
hydroxyhaloC1-4alkoxyC1-4alkyl,
R13,
C1-4alkyl substituted with R13,
C1-4alkyl substituted with —C(═O)—R13,
C1-4alkoxy substituted with R13,
C1-4alkoxy substituted with —C(═O)—R13,
—C(═O)—R13,
C1-4alkyl substituted with —NR7R8,
C1-4alkyl substituted with —C(═O)—NR7R8,
C1-4alkoxy substituted with —NR7R8,
C1-4alkoxy substituted with —C(═O)—NR7R8,
—NR7R8 and
—C(═O)—NR7R8; or
when two R2 groups are attached to adjacent carbon atoms they are optionally taken together to form a radical of formula:
—O—(C(R17)2)p—O—;
—X—CH═CH—; or
—X—CH═N—; wherein R17 is hydrogen or fluorine, p is 1 or 2 and X is O or S;
R3 is
hydroxyl,
C1-6alkoxy,
hydroxyC1-6alkoxy,
C1-6alkoxy substituted with —NR10R11,
C1-6alkyl,
C2-6alkenyl,
C2-6alkynyl,
haloC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC2-6alkenyl,
hydroxyC2-6alkynyl,
hydroxyhaloC1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with carboxyl,
C1-6alkyl substituted with —C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—O—C1-6alkyl,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-O—C(═O)—,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-C(═O)—,
C1-6alkyl substituted with —O—C(═O)—C1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups or with —O—C(═O)—C1-6alkyl,
C2-6alkenyl substituted with C1-6alkoxy,
C2-6alkynyl substituted with C1-6alkoxy,
C1-6alkyl substituted with R9 and optionally substituted with —O—C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—R9,
C1-6alkyl substituted with hydroxyl and R9,
C2-6alkenyl substituted with R9,
C2-6alkynyl substituted with R9,
C1-6alkyl substituted with —NR10R11,
C2-6alkenyl substituted with —NR10R11,
C2-6alkynyl substituted with —NR10R11,
C1-6alkyl substituted with hydroxyl and —NR10R11,
C1-6alkyl substituted with one or two halogens and —NR10R11,
—C1-6alkyl-C(R12)═N—O—R12,
C1-6alkyl substituted with —C(═O)—NR10R11,
C1-6alkyl substituted with —O—C(═O)—NR10R11,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NR12—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R13,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
R4 and R5 are each independently
hydrogen,
C1-6alkyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2—NR14R15,
R13 or
C1-6alkyl substituted with R13;
R6 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S; said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl, each optionally and each independently substituted by 1, 2, 3, 4 or 5 substituents, each substituent independently selected from cyano, C1-6alkyl, cyanoC1-6alkyl, hydroxyl, carboxyl, hydroxyC1-6alkyl, halogen, haloC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl-O—C(═O)—, —NR14R15, —C(═O)—NR14R15, C1-6alkyl substituted with —NR14R15, C1-6alkyl substituted with —C(═O)—NR14R15, —S(═O)2—C1-6alkyl, —S(═O)2-haloC1-6alkyl, —S(═O)2—NR14R15, C1-6alkyl substituted with —S(═O)2—C1-6alkyl, C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl, C1-6alkyl substituted with —S(═O)2—NR14R15, C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl, C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl and C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R7 and R8 are each independently hydrogen, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, hydroxyhaloC1-6alkyl or C1-6alkoxyC1-6alkyl;
R9 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl each optionally and each independently substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently selected from
═O,
C1-4alkyl,
hydroxyl,
carboxyl,
hydroxyC1-4alkyl,
cyano,
cyanoC1-4alkyl,
C1-4alkyl-O—C(═O)—,
C1-4alkyl substituted with C1-4alkyl-O—C(═O)—,
C1-4alkyl-C(═O)—,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
halogen,
haloC1-4alkyl,
hydroxyhaloC1-4alkyl,
—NR14R15,
—C(═O)—NR14R15,
—C1-4alkyl substituted with —NR14R15,
C1-4alkyl substituted with —C(═O)—NR14R15,
C1-4alkoxy,
—S(═O)2—C1-4alkyl,
—S(═O)2-haloC1-4alkyl,
—S(═O)2—NR14R15,
C1-4alkyl substituted with —S(═O)2—NR14R15,
C1-4alkyl substituted with —NH—S(═O)2—C1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2-haloC1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2—NR14R15,
R13,
—C(═O)—R13,
C1-4alkyl substituted with R13,
phenyl optionally substituted with R16,
phenylC1-6alkyl wherein the phenyl is optionally substituted with R16, and
a 5 or 6-membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S wherein said heterocyclyl is optionally substituted with R16;
or when two of the substituents of R9 are attached to the same atom, they are optionally taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S;
R10 and R11 are each independently
hydrogen,
carboxyl,
C1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with —NR14R15,
C1-6alkyl substituted with —C(═O)—NR14R15,
haloC1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxy,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
R6,
C1-6alkyl substituted with R6,
—C(═O)—R6,
—C(═O)—C1-6alkyl,
—C(═O)-hydroxyC1-6alkyl,
—C(═O)-haloC1-6alkyl,
—C(═O)-hydroxyhaloC1-6alkyl,
C1-6alkyl substituted with —Si(CH3)3,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl or
C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R12 is hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy;
R13 is C3-8cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, wherein said C3-8cycloalkyl or monocyclic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxyl, C1-6alkyl, —C(═O)—C1-6alkyl, C1-6alkoxy, and —NR14R15;
R14 and R15 are each independently
hydrogen, or
haloC1-4alkyl, or
C1-4alkyl optionally substituted with a substituent selected from hydroxyl, C1-4alkoxy, amino and mono- or di(C1-4alkyl)amino; and
R16 is hydroxyl, halogen, cyano, C1-4alkyl, C1-4alkoxy, —NR14R15 or —C(═O)NR14R15;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein
R1 is
hydrogen,
C1-6alkyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with —NR4R5,
C1-6alkyl substituted with —C(═O)—NR4R5,
—S(═O)2—C1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
R6,
C1-6alkyl substituted with R6,
C1-6alkyl substituted with —C(═O)—R6,
hydroxyC1-6alkyl substituted with R6, or
C1-6alkyl substituted with —Si(CH3)3;
each R1a is hydrogen;
R10 and R11 are each independently
hydrogen,
C1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with —NR14R15,
C1-6alkyl substituted with —C(═O)—NR14R15,
haloC1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxy,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
R6,
C1-6alkyl substituted with R6,
—C(═O)—R6,
—C(═O)—C1-6alkyl,
—C(═O)-hydroxyC1-6alkyl,
—C(═O)-haloC1-6alkyl,
—C(═O)-hydroxyhaloC1-6alkyl,
C1-6alkyl substituted with —Si(CH3)3,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl or
C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein each R1a is hydrogen; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R1 is C1-6alkyl; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R1 is CH3— or CD3-; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R2 is independently selected from halogen, cyano, C1-4alkyl, C2-4alkenyl, C1-4alkoxy, hydroxyC1-4alkyl, hydroxyC1-4alkoxy, haloC1-4alkoxy, C1-4alkoxyC1-4alkyl, R13, C1-4alkoxy substituted with R13, —C(═O)—R13, C1-4alkyl substituted with NR7R8, C1-4alkoxy substituted with NR7R8, —NR7R8 and —C(═O)—NR7R8; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R2 is C1-4alkoxy; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 8 (depends on 6)

A method according to claim 6, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R2 is CH3O— or CD30-; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 9 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R3 is
C1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
haloC1-6alkyl,
C1-6alkyl substituted with —C(═O)—C1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with R9,
C1-6alkyl substituted with —NR10R11,
C1-6alkyl substituted with hydroxyl and —NR10R11,
C1-6alkyl substituted with one or two halogens and —NR10R11,
C1-6alkyl substituted with —C(═O)—O—C1-6alkyl,
C1-6alkyl substituted with —O—C(═O)—NR10R11,
C1-6alkyl substituted with carboxyl,
C1-6alkyl substituted with —NR12—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
C1-6alkyl substituted with hydroxyl and R9,
—C1-6alkyl-C(R12)═N—O—R12,
C1-6alkyl substituted with —C(═O)—NR10R11,
C1-6alkyl substituted with —C(═O)—R9,
C2-6alkynyl substituted with R9,
hydroxyC1-6alkoxy,
C2-6alkenyl,
C2-6alkynyl or
R13;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R1 is C1-6alkyl, each R1a is hydrogen, n is an integer equal to 2, each R2 is C1-4alkoxy, and R3 is C1-6alkyl substituted with —NR10R11; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R10 is hydrogen, —CH3, —CH2CH3 or —CH(CH3)2 and R11 is hydrogen, —CH3, —CH2CH3, —CH(CH3)2, —CH2CF3, —CH2CHF2, —CH2CH2F, —C(═O)—CH3, —S(═O)2—CH3, —S(═O)2—CH2CH3, —S(═O)2—CH(CH3)2, —S(═O)2—N(CH3)2, —CH2CH2OH, —C(═O)—C(OH)(CH3)CF3, —C(═O)-cyclopropyl, —CH2CH2CN, cyclopropane, cyclopentane, 2,2,6,6-tetramethyl-piperidine, —CH2C3H5, —CH2— tetrahydrofuran, —C(═O)-(1-methyl-piperidin-3-yl), —C(═O)—CF3, —CH2Si(CH3)3, or —CH2—C6H5; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 12 (depends on 10)

A method according to claim 10, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R1 is —CH3, each R1a is hydrogen, n is an integer equal to 2, each R2 is CH3O—, and R3 is —CH2CH2NHCH(CH3)2; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 13 (depends on 10)

A method according to claim 10, wherein the compound is selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein R1 is —CH3, each R1a is hydrogen, n is an integer equal to 2, each R2 is CH3O—, and R3 is —CH2CH2—CH2—NHCH2CF3 or —CH2—CH2NH2; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 14 (depends on 1)

A method according to claim 1, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

### Claim 16 (depends on 1)

A method according to claim 1, wherein the compound is selected from:
N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine; and
N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 17 (depends on 16)

A method according to claim 16, wherein the compound is selected from:
N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine; and
N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

### Claim 18

A method for treating a subject suffering from, or being at risk of suffering from cancer,
said method comprising administering to the subject a compound selected from the group consisting of a compound of formula (I)
a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein
n is an integer equal to 0, 1, 2, 3 or 4;
R1 is
hydrogen,
C1-6alkyl,
C2-4alkenyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
cyanoC1-4alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with —NR4R5,
C1-6alkyl substituted with —C(═O)—NR4R5,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R6,
C1-6alkyl substituted with R6,
C1-6alkyl substituted with —C(═O)—R6,
hydroxyC1-6alkyl substituted with R6,
C1-6alkyl substituted with —Si(CH3)3,
C1-6alkyl substituted with —P(═O)(OH)2 or C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
each R1a is independently selected from
hydrogen,
C1-4alkyl,
hydroxyC1-4alkyl,
C1-4alkyl substituted with amino or mono- or di(C1-4alkyl)amino or —NH(C3-8cycloalkyl),
cyanoC1-4alkyl,
C1-4alkoxyC1-4alkyl, and
C1-4alkyl substituted with one or more fluoro atoms;
each R2 is independently selected from
hydroxyl,
halogen,
cyano,
C1-4alkyl,
C2-4alkenyl,
C2-4alkynyl,
C1-4alkoxy,
hydroxyC1-4alkyl,
hydroxyC1-4alkoxy,
haloC1-4alkyl,
haloC1-4alkoxy,
hydroxyhaloC1-4alkyl,
hydroxyhaloC1-4alkoxy,
C1-4alkoxyC1-4alkyl,
haloC1-4alkoxyC1-4alkyl,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
hydroxyhaloC1-4alkoxyC1-4alkyl,
R13,
C1-4alkyl substituted with R13,
C1-4alkyl substituted with —C(═O)—R13,
C1-4alkoxy substituted with R13,
C1-4alkoxy substituted with —C(═O)—R13,
—C(═O)—R13,
C1-4alkyl substituted with —NR7R8,
C1-4alkyl substituted with —C(═O)—NR7R8,
C1-4alkoxy substituted with —NR7R8,
C1-4alkoxy substituted with —C(═O)—NR7R8,
—NR7R8 and —C(═O)—NR7R8; or
when two R2 groups are attached to adjacent carbon atoms they are optionally taken together to form a radical of formula:
—O—(C(R17)2)p—O—;
—X—CH═CH—; or
—X—CH═N—; wherein R17 is hydrogen or fluorine, p is 1 or 2 and X is O or S;
R3 is
hydroxyl,
C1-6alkoxy,
hydroxyC1-6alkoxy,
C1-6alkoxy substituted with —NR11R11,
C1-6alkyl,
C2-6alkenyl,
C2-6alkynyl,
haloC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC2-6alkenyl,
hydroxyC2-6alkynyl,
hydroxyhaloC1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with carboxyl,
C1-6alkyl substituted with —C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—O—C1-6alkyl,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-O—C(═O)—,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-C(═O)—,
C1-6alkyl substituted with —O—C(═O)—C1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups or with —O—C(═O)—C1-6alkyl,
C2-6alkenyl substituted with C1-6alkoxy,
C2-6alkynyl substituted with C1-6alkoxy,
C1-6alkyl substituted with R9 and optionally substituted with —O—C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—R9,
C1-6alkyl substituted with hydroxyl and R9,
C2-6alkenyl substituted with R9,
C2-6alkynyl substituted with R9,
C1-6alkyl substituted with —NR10R11,
C2-6alkenyl substituted with —NR10R11,
C2-6alkynyl substituted with —NR10R11,
C1-6alkyl substituted with hydroxyl and —NR10R11,
C1-6alkyl substituted with one or two halogens and —NR10R11,
—C1-6alkyl-C(R12)═N—O—R12,
C1-6alkyl substituted with —C(═O)—NR10R11,
C1-6alkyl substituted with —O—C(═O)—NR10R11,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NR12—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R13,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
R4 and R5 are each independently
hydrogen,
C1-6alkyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2—NR14R15,
R13 or
C1-6alkyl substituted with R13;
R6 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S; said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl, each optionally and each independently substituted by 1, 2, 3, 4 or 5 substituents, each substituent independently selected from cyano, C1-6alkyl, cyanoC1-6alkyl, hydroxyl, carboxyl, hydroxyC1-6alkyl, halogen, haloC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl-O—C(═O)—, —NR14R15, —C(═O)—NR14R15, C1-6alkyl substituted with —NR14R15, C1-6alkyl substituted with —C(═O)—NR14R15, —S(═O)2—C1-6alkyl, —S(═O)2-haloC1-6alkyl, —S(═O)2—NR14R15, C1-6alkyl substituted with —S(═O)2—C1-6alkyl, C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl, C1-6alkyl substituted with —S(═O)2—NR14R15, C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl, C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl and C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R7 and R8 are each independently hydrogen, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, hydroxyhaloC1-6alkyl or C1-6alkoxyC1-6alkyl;
R9 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl each optionally and each independently substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently selected from
═O,
C1-4alkyl,
hydroxyl,
carboxyl,
hydroxyC1-4alkyl,
cyano,
cyanoC1-4alkyl,
C1-4alkyl-O—C(═O)—,
C1-4alkyl substituted with C1-4alkyl-O—C(═O)—,
C1-4alkyl-C(═O)—,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
halogen,
haloC1-4alkyl,
hydroxyhaloC1-4alkyl,
—NR14R15,
—C(═O)—NR14R15,
C1-4alkyl substituted with —NR14R15,
C1-4alkyl substituted with —C(═O)—NR14R15,
C1-4alkoxy,
—S(═O)2—C1-4alkyl,
—S(═O)2-haloC1-4alkyl,
—S(═O)2—NR14R15,
C1-4alkyl substituted with —S(═O)2—NR14R15,
C1-4alkyl substituted with —NH—S(═O)2—C1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2-haloC1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2—NR14R15,
R13,
—C(═O)—R13,
C1-4alkyl substituted with R13,
phenyl optionally substituted with R16,
phenylC1-6alkyl wherein the phenyl is optionally substituted with R16, and a 5 or 6-membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S wherein said heterocyclyl is optionally substituted with R16;
or when two of the substituents of R9 are attached to the same atom, they are optionally taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S;
R10 and R11 are each independently
hydrogen,
carboxyl,
C1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with —NR14R15,
C1-6alkyl substituted with —C(═O)—NR14R15,
haloC1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxy,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
R6,
C1-6alkyl substituted with R6,
—C(═O)—R6,
—C(═O)—C1-6alkyl,
—C(═O)-hydroxyC1-6alkyl,
—C(═O)-haloC1-6alkyl,
—C(═O)-hydroxyhaloC1-6alkyl,
C1-6alkyl substituted with —Si(CH3)3,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl or
C1-6alkyl substituted with —NH—S(═O)2—NR14R14R15;
R12 is hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy;
R13 is C3-8cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, wherein said C3-8cycloalkyl or monocyclic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxyl, C1-6alkyl, —C(═O)—C1-6alkyl, C1-6alkoxy, and —NR14R15;
R14 and R15 are each independently
hydrogen, or
haloC1-4alkyl, or
C1-4alkyl optionally substituted with a substituent selected from hydroxyl, C1-4alkoxy, amino and mono- or di(C1-4alkyl)amino; and
R16 is hydroxyl, halogen, cyano, C1-4alkyl, C1-4alkoxy, —NR14R15 or —C(═O)NR14R15;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 19 (depends on 18)

A method according to claim 18, wherein the cancer is selected from multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, and oral squamous cell carcinoma.

### Claim 20 (depends on 18)

A method according to claim 18, wherein the cancer is selected from lung cancer, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer, colon cancer, colorectal cancer, and prostate cancer.

### Claim 21 (depends on 19)

A method according to claim 19, wherein the cancer is multiple myeloma.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the cancer is t(4;14) translocation positive multiple myeloma.

### Claim 23 (depends on 19)

A method according to claim 19, wherein the cancer is bladder cancer.

### Claim 24 (depends on 23)

A method according to claim 23, wherein the cancer is bladder cancer with a FGFR3 chromosomal translocation.

### Claim 25 (depends on 23)

A method according to claim 23, wherein the cancer is bladder cancer with a FGFR3 point mutation.

### Claim 26 (depends on 18)

A method according to claim 18, wherein the cancer is a tumor with a mutant of FGFR1, FGFR2, FGFR3 or FGFR4.

### Claim 27 (depends on 18)

A method according to claim 18, wherein the cancer is a tumor with a gain-of-function mutant of FGFR2 or FGFR3.

### Claim 28 (depends on 18)

A method according to claim 18, wherein the cancer is a tumor with over-expression of FGFR1.

### Claim 29 (depends on 18)

A method according to claim 18, wherein the cancer is urothelial carcinoma.

### Claim 30 (depends on 18)

A method according to claim 18, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 31 (depends on 30)

A method according to claim 30, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

### Claim 32 (depends on 18)

A method according to claim 18, wherein the compound is selected from:
N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine; and
N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 33

A method for treating a subject suffering from, or being at risk of suffering from a carcinoma, wherein the carcinoma is selected from a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, head and neck, gall bladder, ovary, pancreas, stomach, gastrointestinal (also known as gastric) cancer, cervix, endometrium, thyroid, prostate, or skin, a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; multiple myeloma; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; or Kaposi's sarcoma, said method comprising administering to the subject a compound selected from the group consisting of a compound of formula (I)
a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein
n is an integer equal to 0, 1, 2, 3 or 4;
R1 is
hydrogen,
C1-6alkyl,
C2-4alkenyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
cyanoC1-4alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with —NR4R5,
C1-6alkyl substituted with —C(═O)—NR4R5,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R6,
C1-6alkyl substituted with R6,
C1-6alkyl substituted with —C(═O)—R6,
hydroxyC1-6alkyl substituted with R6,
C1-6alkyl substituted with —Si(CH3)3,
C1-6alkyl substituted with —P(═O)(OH)2 or C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
each R1a is independently selected from
hydrogen,
C1-4alkyl,
hydroxyC1-4alkyl,
C1-4alkyl substituted with amino or mono- or di(C1-4alkyl)amino or —NH(C3-8cycloalkyl),
cyanoC1-4alkyl,
C1-4alkoxyC1-4alkyl, and
C1-4alkyl substituted with one or more fluoro atoms;
each R2 is independently selected from
hydroxyl,
halogen,
cyano,
C1-4alkyl,
C2-4alkenyl,
C2-4alkynyl,
C1-4alkoxy,
hydroxyC1-4alkyl,
hydroxyC1-4alkoxy,
haloC1-4alkyl,
haloC1-4alkoxy,
hydroxyhaloC1-4alkyl,
hydroxyhaloC1-4alkoxy,
C1-4alkoxyC1-4alkyl,
haloC1-4alkoxyC1-4alkyl,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
hydroxyhaloC1-4alkoxyC1-4alkyl,
R13,
C1-4alkyl substituted with R13,
C1-4alkyl substituted with —C(═O)—R13,
C1-4alkoxy substituted with R13,
C1-4alkoxy substituted with —C(═O)—R13,
—C(═O)—R13,
C1-4alkyl substituted with —NR7R8,
C1-4alkyl substituted with —C(═O)—NR7R8,
C1-4alkoxy substituted with —NR7R8,
C1-4alkoxy substituted with —C(═O)—NR7R8,
—NR7R8 and —C(═O)—NR7R8; or
when two R2 groups are attached to adjacent carbon atoms they are optionally taken together to form a radical of formula:
—O—(C(R17)2)p—O—;
—X—CH═CH—; or
—X—CH═N—; wherein R17 is hydrogen or fluorine, p is 1 or 2 and X is O or S;
R3 is
hydroxyl,
C1-6alkoxy,
hydroxyC1-6alkoxy,
C1-6alkoxy substituted with —NR11R11,
C1-6alkyl,
C2-6alkenyl,
C2-6alkynyl,
haloC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC2-6alkenyl,
hydroxyC2-6alkynyl,
hydroxyhaloC1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with carboxyl,
C1-6alkyl substituted with —C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—O—C1-6alkyl,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-O—C(═O)—,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-C(═O)—,
C1-6alkyl substituted with —O—C(═O)—C1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups or with —O—C(═O)—C1-6alkyl,
C2-6alkenyl substituted with C1-6alkoxy,
C2-6alkynyl substituted with C1-6alkoxy,
C1-6alkyl substituted with R9 and optionally substituted with —O—C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—R9,
C1-6alkyl substituted with hydroxyl and R9,
C2-6alkenyl substituted with R9,
C2-6alkynyl substituted with R9,
C1-6alkyl substituted with —NR10R11,
C2-6alkenyl substituted with —NR10R11,
C2-6alkynyl substituted with —NR10R11,
C1-6alkyl substituted with hydroxyl and —NR10R11,
C1-6alkyl substituted with one or two halogens and —NR10R11,
—C1-6alkyl-C(R12)═N—O—R12,
C1-6alkyl substituted with —C(═O)—NR10R11,
C1-6alkyl substituted with —O—C(═O)—NR10R11,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NR12—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R13,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
R4 and R5 are each independently
hydrogen,
C1-6alkyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2—NR14R15,
R13 or
C1-6alkyl substituted with R13;
R6 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S; said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl, each optionally and each independently substituted by 1, 2, 3, 4 or 5 substituents, each substituent independently selected from cyano, C1-6alkyl, cyanoC1-6alkyl, hydroxyl, carboxyl, hydroxyC1-6alkyl, halogen, haloC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl-O—C(═O)—, —NR14R15, —C(═O)—NR14R15, C1-6alkyl substituted with —NR14R15, C1-6alkyl substituted with —C(═O)—NR14R15, —S(═O)2—C1-6alkyl, —S(═O)2-haloC1-6alkyl, —S(═O)2—NR14R15, C1-6alkyl substituted with —S(═O)2—C1-6alkyl, C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl, C1-6alkyl substituted with —S(═O)2—NR14R15, C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl, C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl and C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R7 and R8 are each independently hydrogen, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, hydroxyhaloC1-6alkyl or C1-6alkoxyC1-6alkyl;
R9 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl each optionally and each independently substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently selected from
═O,
C1-4alkyl,
hydroxyl,
carboxyl,
hydroxyC1-4alkyl,
cyano,
cyanoC1-4alkyl,
C1-4alkyl-O—C(═O)—,
C1-4alkyl substituted with C1-4alkyl-O—C(═O)—,
C1-4alkyl-C(═O)—,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
halogen,
haloC1-4alkyl,
hydroxyhaloC1-4alkyl,
—NR14R15,
—C(═O)—NR14R15,
C1-4alkyl substituted with —NR14R15,
C1-4alkyl substituted with —C(═O)—NR14R15,
C1-4alkoxy,
—S(═O)2—C1-4alkyl,
—S(═O)2-haloC1-4alkyl,
—S(═O)2—NR14R15,
C1-4alkyl substituted with —S(═O)2—NR14R15,
C1-4alkyl substituted with —NH—S(═O)2—C1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2-haloC1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2—NR14R15,
R13,
—C(═O)—R13,
C1-4alkyl substituted with R13,
phenyl optionally substituted with R16,
phenylC1-6alkyl wherein the phenyl is optionally substituted with R16, and a 5 or 6-membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S wherein said heterocyclyl is optionally substituted with R16;
or when two of the substituents of R9 are attached to the same atom, they are optionally taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S;
R10 and R11 are each independently
hydrogen,
carboxyl,
C1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with —NR14R15,
C1-6alkyl substituted with —C(═O)—NR14R15,
haloC1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxy,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
R6,
C1-6alkyl substituted with R6,
—C(═O)—R6,
—C(═O)—C1-6alkyl,
—C(═O)-hydroxyC1-6alkyl,
—C(═O)-haloC1-6alkyl,
—C(═O)-hydroxyhaloC1-6alkyl,
C1-6alkyl substituted with —Si(CH3)3,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl or C1-6alkyl substituted with —NH—S(═O)2—NR14R14R15;
R12 is hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy;
R13 is C3-8cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, wherein said C3-8cycloalkyl or monocyclic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxyl, C1-6alkyl, —C(═O)—C1-6alkyl, C1-6alkoxy, and —NR14R15;
R14 and R15 are each independently
hydrogen, or
haloC1-4alkyl, or
C1-4alkyl optionally substituted with a substituent selected from hydroxyl, C1-4alkoxy, amino and mono- or di(C1-4alkyl)amino; and
R16 is hydroxyl, halogen, cyano, C1-4alkyl, C1-4alkoxy, —NR14R15 or —C(═O)NR14R15;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 34 (depends on 33)

A method according to claim 33, wherein the carcinoma is glioblastoma multiforme.

### Claim 35 (depends on 33)

A method according to claim 33, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 36 (depends on 35)

A method according to claim 35, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

### Claim 37

A method of inhibiting a FGFR kinase, which method comprises contacting the kinase with a kinase-inhibiting compound selected from the group consisting of a compound of formula (I)
a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein
n is an integer equal to 0, 1, 2, 3 or 4;
R1 is
hydrogen,
C1-6alkyl,
C2-4alkenyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
cyanoC1-4alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with —NR4R5,
C1-6alkyl substituted with —C(═O)—NR4R5,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R6,
C1-6alkyl substituted with R6,
C1-6alkyl substituted with —C(═O)—R6,
hydroxyC1-6alkyl substituted with R6,
C1-6alkyl substituted with —Si(CH3)3,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
each R1a is independently selected from
hydrogen,
C1-4alkyl,
hydroxyC1-4alkyl,
C1-4alkyl substituted with amino or mono- or di(C1-4alkyl)amino or —NH(C3-8cycloalkyl),
cyanoC1-4alkyl,
C1-4alkoxyC1-4alkyl, and
C1-4alkyl substituted with one or more fluoro atoms;
each R2 is independently selected from
hydroxyl,
halogen,
cyano,
C1-4alkyl,
C2-4alkenyl,
C2-4alkynyl,
C1-4alkoxy,
hydroxyC1-4alkyl,
hydroxyC1-4alkoxy,
haloC1-4alkyl,
haloC1-4alkoxy,
hydroxyhaloC1-4alkyl,
hydroxyhaloC1-4alkoxy,
C1-4alkoxyC1-4alkyl,
haloC1-4alkoxyC1-4alkyl,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
hydroxyhaloC1-4alkoxyC1-4alkyl,
R13,
C1-4alkyl substituted with R13,
C1-4alkyl substituted with —C(═O)—R13,
C1-4alkoxy substituted with R13,
C1-4alkoxy substituted with —C(═O)—R13,
—C(═O)—R13,
C1-4alkyl substituted with —NR7R8,
C1-4alkyl substituted with —C(═O)—NR7R8,
C1-4alkoxy substituted with —NR7R8,
C1-4alkoxy substituted with —C(═O)—NR7R8,
—NR7R8 and
—C(═O)—NR7R8; or
when two R2 groups are attached to adjacent carbon atoms they are optionally taken together to form a radical of formula:
—O—(C(R17)2)p—O—;
—X—CH═CH—; or
—X—CH═N—; wherein R17 is hydrogen or fluorine, p is 1 or 2 and X is O or S;
R3 is
hydroxyl,
C1-6alkoxy,
hydroxyC1-6alkoxy,
C1-6alkoxy substituted with —NR10R11,
C1-6alkyl,
C2-6alkenyl,
C2-6alkynyl,
haloC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC2-6alkenyl,
hydroxyC2-6alkynyl,
hydroxyhaloC1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with carboxyl,
C1-6alkyl substituted with —C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—O—C1-6alkyl,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-O—C(═O)—,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-C(═O)—,
C1-6alkyl substituted with —O—C(═O)—C1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups or with —O—C(═O)—C1-6alkyl,
C2-6alkenyl substituted with C1-6alkoxy,
C2-6alkynyl substituted with C1-6alkoxy,
C1-6alkyl substituted with R9 and optionally substituted with —O—C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—R9,
C1-6alkyl substituted with hydroxyl and R9,
C2-6alkenyl substituted with R9,
C2-6alkynyl substituted with R9,
C1-6alkyl substituted with —NR10R11,
C2-6alkenyl substituted with —NR10R11,
C2-6alkynyl substituted with —NR10R11,
C1-6alkyl substituted with hydroxyl and —NR10R11,
C1-6alkyl substituted with one or two halogens and —NR10R11,
C1-6alkyl-C(R12)═N—O—R12,
C1-6alkyl substituted with —C(═O)—NR10R11,
C1-6alkyl substituted with —O—C(═O)—NR10R11,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NR12—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R13,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
R4 and R5 are each independently
hydrogen,
C1-6alkyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2—NR14R15,
R13 or
C1-6alkyl substituted with R13;
R6 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S; said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl, each optionally and each independently substituted by 1, 2, 3, 4 or 5 substituents, each substituent independently selected from cyano, C1-6alkyl, cyanoC1-6alkyl, hydroxyl, carboxyl, hydroxyC1-6alkyl, halogen, haloC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl-O—C(═O)—, —NR14R15, —C(═O)—NR14R15, C1-6alkyl substituted with —NR14R15, C1-6alkyl substituted with —C(═O)—NR14R15, —S(═O)2—C1-6alkyl, —S(═O)2-haloC1-6alkyl, —S(═O)2—NR14R15, C1-6alkyl substituted with —S(═O)2—C1-6alkyl, C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl, C1-6alkyl substituted with —S(═O)2—NR14R15, C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl, C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl and C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R7 and R8 are each independently hydrogen, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, hydroxyhaloC1-6alkyl or C1-6alkoxyC1-6alkyl;
R9 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl each optionally and each independently substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently selected from
═O,
C1-4alkyl,
hydroxyl,
carboxyl,
hydroxyC1-4alkyl,
cyano,
cyanoC1-4alkyl,
C1-4alkyl-O—C(═O)—,
C1-4alkyl substituted with C1-4alkyl-O—C(═O)—,
C1-4alkyl-C(═O)—,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
halogen,
haloC1-4alkyl,
hydroxyhaloC1-4alkyl,
—NR14R15,
—C(═O)—NR14R15,
C1-4alkyl substituted with —NR14R15C1-4alkyl substituted with —C(═O)—NR14R15,
C1-4alkoxy,
—S(═O)2—C1-4alkyl,
—S(═O)2-haloC1-4alkyl,
—S(═O)2—NR14R15,
C1-4alkyl substituted with —S(═O)2—NR14R15,
C1-4alkyl substituted with —NH—S(═O)2—C1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2-haloC1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2—NR14R15,
R13,
—C(═O)—R13,
C1-4alkyl substituted with R13,
phenyl optionally substituted with R16,
phenylC1-6alkyl wherein the phenyl is optionally substituted with R16, and a 5 or 6-membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S wherein said heterocyclyl is optionally substituted with R16;
or when two of the substituents of R9 are attached to the same atom, they are optionally taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S;
R10 and R11 are each independently
hydrogen,
carboxyl,
C1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with —NR14R15,
C1-6alkyl substituted with —C(═O)—NR14R15,
haloC1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxy,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
R6,
C1-6alkyl substituted with R6,
—C(═O)—R6,
—C(═O)—C1-6alkyl,
—C(═O)-hydroxyC1-6alkyl,
—C(═O)-haloC1-6alkyl,
—C(═O)-hydroxyhaloC1-6alkyl,
C1-6alkyl substituted with —Si(CH3)3,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl or
C1-6alkyl substituted with —NH—S(═O)2—NR14R14R15;
R12 is hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy;
R13 is C3-8cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, wherein said C3-8cycloalkyl or monocyclic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxyl, C1-6alkyl, —C(═O)—C1-6alkyl, C1-6alkoxy, and —NR14R15;
R14 and R15 are each independently
hydrogen, or
haloC1-4alkyl, or
C1-4alkyl optionally substituted with a substituent selected from hydroxyl, C1-4alkoxy, amino and mono- or di(C1-4alkyl)amino; and
R16 is hydroxyl, halogen, cyano, C1-4alkyl, C1-4alkoxy, —NR14R15 or —C(═O)NR14R15;
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 38 (depends on 37)

A method according to claim 37, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 39 (depends on 38)

A method according to claim 38, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

### Claim 40 (depends on 1)

A method according to claim 1, further comprising administering to the subject one or more other anticancer agents.

### Claim 41 (depends on 40)

A method according to claim 40, wherein the one or more other anticancer agents comprises a kinase inhibitor.

### Claim 42 (depends on 40)

A method according to claim 40, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 43 (depends on 42)

A method according to claim 42, wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

### Claim 44

A process for the preparation of a compound selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof, or an N-oxide, a pharmaceutically acceptable salt, or a solvate of the compound, said process comprising:
(i) deprotecting a compound of formula (XXX) wherein P represents a suitable protective group, in the presence of a suitable acid,
(ii) the reaction of a compound of the formula (IX) or (IX′):
or a protected form thereof, with an appropriately substituted amine or a reactive derivative thereof, in the presence of a suitable base, and/or in the presence or absence of a solvent; or
(iii) the reaction of a compound of the formula (VI):
or a protected form thereof, with a compound of formula W6—C1-6alkyl-NR10P wherein P represents a suitable protective group and W6 represents a suitable leaving group, in the presence of a suitable base, and a suitable solvent, followed by removing P and optionally removing any further protecting group present; or
(iv) the reaction of a compound of the formula (VI):
or a protected form thereof, with a compound of formula W6—C1-6alkyl-NHR10 wherein W6 represents a suitable leaving group, in the presence of a suitable base, and a suitable solvent;
(v) the reaction of a compound of formula (XXXVI)
with hydrazine in the presence of a suitable solvent; or
(vi) the reaction of a compound of formula (IX-1) wherein Ru represents —O—S(═O)2—CH3,
with an intermediate of formula (X) in the presence of a suitable solvent; or
(vii) the reaction of a compound of formula (VI)
with an intermediate of formula W11—R3b wherein R3b represents optionally substituted C2-6alkynyl and W11 represents a suitable leaving group, in the presence of a suitable base and a suitable solvent; or
(viii) the reaction of a compound of formula (VIII′) wherein Rx and Ry represent C1-4alkyl, and Rz represents C1-4alkyl or phenyl,
with a suitable acid, in the presence of a suitable solvent; or
(viii) deprotecting a compound of formula (XXXXII)
in the presence of a suitable base and a suitable solvent; or
(ix) the reaction of a compound of formula (VI)
with di(C1-6alkyl)vinylphosphonate in the presence of a suitable catalyst and a suitable solvent; or
(x) deprotecting a compound of formula (XXXXI) wherein P represents a suitable protective group
in the presence of a suitable base and a suitable solvent; or
(xi) the reaction of a compound of formula (XIX) wherein R3a represents optionally substituted C1-6alkyl, with a compound of formula (III)
in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent; or
(xii) the reaction of a compound of formula (XX) wherein R3a represents optionally substituted C1-6alkyl, with a compound of formula (XIV) wherein W5 represents a suitable leaving group
in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent; or
(xiii) the reaction of a compound of formula (XXXI)
with W8—CN, wherein W8 represents a suitable leaving group, in the presence of a suitable base and a suitable solvent; or
(xiv) the reaction of a compound of formula (XXXV)
with a suitable base in the presence of a suitable solvent; or
(xv) deprotecting a compound of formula (XXVI) wherein P represents a suitable protective group,
in the presence of a suitable acid, or a suitable de-silylating agent, and a suitable solvent; or
(xvi) the reaction of a compound of formula (XXIX) with a compound of formula (XXI)
in the presence of suitable peptide coupling reagents; or
(xvii) the reaction of a compound of formula (XXIX)
with NHR4R5 in the presence of suitable peptide coupling reagents and a suitable base, and a suitable solvent; or
(xviii) reacting the below compound
with NHR7R8 in the presence of a suitable base and a suitable solvent; or
(xviii) deprotecting the below compound
in the presence of hydrazine monohydrate and a suitable solvent;
wherein
n is an integer equal to 0, 1, 2, 3 or 4;
R1 is
hydrogen,
C1-6alkyl,
C2-4alkenyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
cyanoC1-4alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
C1-6alkyl substituted with —NR4R5,
C1-6alkyl substituted with —C(═O)—NR4R5,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R6,
C1-6alkyl substituted with R6,
C1-6alkyl substituted with —C(═O)—R6,
hydroxyC1-6alkyl substituted with R6,
C1-6alkyl substituted with —Si(CH3)3,
C1-6alkyl substituted with —P(═O)(OH)2 or C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
each R1a is independently selected from
hydrogen,
C1-4alkyl,
hydroxyC1-4alkyl,
C1-4alkyl substituted with amino or mono- or di(C1-4alkyl)amino or —NH(C3-8cycloalkyl),
cyanoC1-4alkyl,
C1-4alkoxyC1-4alkyl, and
C1-4alkyl substituted with one or more fluoro atoms;
each R2 is independently selected from
hydroxyl,
halogen,
cyano,
C1-4alkyl,
C2-4alkenyl,
C2-4alkynyl,
C1-4alkoxy,
hydroxyC1-4alkyl,
hydroxyC1-4alkoxy,
haloC1-4alkyl,
haloC1-4alkoxy,
hydroxyhaloC1-4alkyl,
hydroxyhaloC1-4alkoxy,
C1-4alkoxyC1-4alkyl,
haloC1-4alkoxyC1-4alkyl,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
hydroxyhaloC1-4alkoxyC1-4alkyl,
R13,
C1-4alkyl substituted with R13,
C1-4alkyl substituted with —C(═O)—R13,
C1-4alkoxy substituted with R13,
C1-4alkoxy substituted with —C(═O)—R13,
—C(═O)—R13,
C1-4alkyl substituted with —NR7R8,
C1-4alkyl substituted with —C(═O)—NR7R8,
C1-4alkoxy substituted with —NR7R8,
C1-4alkoxy substituted with —C(═O)—NR7R8,
—NR7R8 and —C(═O)—NR7R8; or
when two R2 groups are attached to adjacent carbon atoms they are optionally taken together to form a radical of formula:
—O—(C(R17)2)p—O—;
—X—CH═CH—; or
—X—CH═N—; wherein R17 is hydrogen or fluorine, p is 1 or 2 and X is O or S;
R3 is
hydroxyl,
C1-6alkoxy,
hydroxyC1-6alkoxy,
C1-6alkoxy substituted with —NR10R11,
C1-6alkyl,
C2-6alkenyl,
C2-6alkynyl,
haloC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC1-6alkyl optionally substituted with —O—C(═O)—C1-6alkyl,
hydroxyC2-6alkenyl,
hydroxyC2-6alkynyl,
hydroxyhaloC1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with carboxyl,
C1-6alkyl substituted with —C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—O—C1-6alkyl,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-O—C(═O)—,
C1-6alkyl substituted with C1-6alkoxyC1-6alkyl-C(═O)—,
C1-6alkyl substituted with —O—C(═O)—C1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups or with —O—C(═O)—C1-6alkyl,
C2-6alkenyl substituted with C1-6alkoxy,
C2-6alkynyl substituted with C1-6alkoxy,
C1-6alkyl substituted with R9 and optionally substituted with —O—C(═O)—C1-6alkyl,
C1-6alkyl substituted with —C(═O)—R9,
C1-6alkyl substituted with hydroxyl and R9,
C2-6alkenyl substituted with R9,
C2-6alkynyl substituted with R9,
C1-6alkyl substituted with —NR10R11,
C2-6alkenyl substituted with —NR10R11,
C2-6alkynyl substituted with —NR10R11,
C1-6alkyl substituted with hydroxyl and —NR10R11,
C1-6alkyl substituted with one or two halogens and —NR10R11,
—C1-6alkyl-C(R12)═N—O—R12,
C1-6alkyl substituted with —C(═O)—NR10R11,
C1-6alkyl substituted with —O—C(═O)—NR10R11,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NR12—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NR12—S(═O)2—NR14R15,
R13,
C1-6alkyl substituted with —P(═O)(OH)2 or
C1-6alkyl substituted with —P(═O)(OC1-6alkyl)2;
R4 and R5 are each independently
hydrogen,
C1-6alkyl,
hydroxyC1-6alkyl,
haloC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2—NR14R15,
R13 or
C1-6alkyl substituted with R13;
R6 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S; said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl, each optionally and each independently substituted by 1, 2, 3, 4 or 5 substituents, each substituent independently selected from cyano, C1-6alkyl, cyanoC1-6alkyl, hydroxyl, carboxyl, hydroxyC1-6alkyl, halogen, haloC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl-O—C(═O)—, —NR14R15, —C(═O)—NR14R15, C1-6alkyl substituted with —NR14R15, C1-6alkyl substituted with —C(═O)—NR14R15, —S(═O)2—C1-6alkyl, —S(═O)2-haloC1-6alkyl, —S(═O)2—NR14R15, C1-6alkyl substituted with —S(═O)2—C1-6alkyl, C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl, C1-6alkyl substituted with —S(═O)2—NR14R15, C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl, C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl and C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R7 and R8 are each independently hydrogen, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, hydroxyhaloC1-6alkyl or C1-6alkoxyC1-6alkyl;
R9 is C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said C3-8cycloalkyl, C3-8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl each optionally and each independently substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently selected from
═O,
C1-4alkyl,
hydroxyl,
carboxyl,
hydroxyC1-4alkyl,
cyano,
cyanoC1-4alkyl,
C1-4alkyl-O—C(═O)—,
C1-4alkyl substituted with C1-4alkyl-O—C(═O)—,
C1-4alkyl-C(═O)—,
C1-4alkoxyC1-4alkyl wherein each C1-4alkyl is optionally substituted with one or two hydroxyl groups,
halogen,
haloC1-4alkyl,
hydroxyhaloC1-4alkyl,
—NR14R15,
—C(═O)—NR14R15,
C1-4alkyl substituted with —NR14R15,
C1-4alkyl substituted with —C(═O)—NR14R15,
C1-4alkoxy,
—S(═O)2—C1-4alkyl,
—S(═O)2-haloC1-4alkyl,
—S(═O)2—NR14R15,
C1-4alkyl substituted with —S(═O)2—NR14R15,
C1-4alkyl substituted with —NH—S(═O)2—C1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2-haloC1-4alkyl,
C1-4alkyl substituted with —NH—S(═O)2—NR14R15,
R13,
—C(═O)—R13C1-4alkyl substituted with R13,
phenyl optionally substituted with R16,
phenylC1-6alkyl wherein the phenyl is optionally substituted with R16, and a 5 or 6-membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S wherein said heterocyclyl is optionally substituted with R16;
or when two of the substituents of R9 are attached to the same atom, they are optionally taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S;
R10 and R11 are each independently
hydrogen,
carboxyl,
C1-6alkyl,
cyanoC1-6alkyl,
C1-6alkyl substituted with —NR14R15,
C1-6alkyl substituted with —C(═O)—NR14R15,
haloC1-6alkyl,
hydroxyC1-6alkyl,
hydroxyhaloC1-6alkyl,
C1-6alkoxy,
C1-6alkoxyC1-6alkyl wherein each C1-6alkyl is optionally substituted with one or two hydroxyl groups,
R6,
C1-6alkyl substituted with R6,
—C(═O)—R6,
—C(═O)—C1-6alkyl,
—C(═O)-hydroxyC1-6alkyl,
—C(═O)-haloC1-6alkyl,
—C(═O)-hydroxyhaloC1-6alkyl,
C1-6alkyl substituted with —Si(CH3)3,
—S(═O)2—C1-6alkyl,
—S(═O)2-haloC1-6alkyl,
—S(═O)2—NR14R15,
C1-6alkyl substituted with —S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —S(═O)2-haloC1-6alkyl,
C1-6alkyl substituted with —S(═O)2—NR14R15,
C1-6alkyl substituted with —NH—S(═O)2—C1-6alkyl,
C1-6alkyl substituted with —NH—S(═O)2-haloC1-6alkyl or
C1-6alkyl substituted with —NH—S(═O)2—NR14R15;
R12 is hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy;
R13 is C3-8cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, wherein said C3-8cycloalkyl or monocyclic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxyl, C1-6alkyl, —C(═O)—C1-6alkyl, C1-6alkoxy, and —NR14R15;
R14 and R15 are each independently
hydrogen, or
haloC1-4alkyl, or
C1-4alkyl optionally substituted with a substituent selected from hydroxyl, C1-4alkoxy, amino and mono- or di(C1-4alkyl)amino; and
R16 is hydroxyl, halogen, cyano, C1-4alkyl, C1-4alkoxy, —NR14R15 or —C(═O)NR14R15;
and optionally thereafter converting one compound selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof into another compound selected from the group consisting of a compound of formula (I), a tautomeric form, stereochemically isomeric form and isotopic form thereof.

### Claim 45 (depends on 44)

A process according to claim 44, said process comprising:
(ii) the reaction of a compound of the formula (IX) or (IX′):
or a protected form thereof, with an appropriately substituted amine or a reactive derivative thereof, selected from NHR10R11 (X), NHR10P(X-a), and a suitable nitrogen containing ring within the definition of R9:H- (XXI), optionally in a sealed vessel, in the presence of a suitable base, and/or in the presence or absence of a solvent.
